Regulators around the world are coming under pressure from patients, clinicians, and industry groups to streamline the market approval process for highly novel biomedical technologies, including stem cells and regenerative medicine products. The rationale for streamlining this process centers on the perceived failures of regulatory systems to encourage biomedical innovation and provide patients with timely access to potentially beneficial yet experimental therapies. Critics claim that the process of generating scientific evidence in phased clinical trials is too costly, time-consuming, and poorly suited for stem cell–based products that, unlike bio-pharmaceuticals, are intended to engraft into the body for long...
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1353/pbm.2018.0027
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy

Upload a copy of this paper     Check publisher's policy     Papers currently archived: 72,564
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library

References found in this work BETA

No references found.

Add more references

Citations of this work BETA

No citations found.

Add more citations

Similar books and articles

Stem Cells Therapy and Research. Benefits and Ethical Challences.Nicolae Ovidiu Grad, Ionel Ciprian Pop & Ion Aurel Mironiuc - 2012 - Journal for the Study of Religions and Ideologies 11 (32):190-205.


Added to PP index

Total views
14 ( #737,950 of 2,533,564 )

Recent downloads (6 months)
1 ( #390,861 of 2,533,564 )

How can I increase my downloads?


My notes